深圳粒影生物科技有限公司重组三螺旋结构胶原蛋白已正式被纳入国际化妆品原料（INCI）目录（INCI编号40302），这是胶原蛋白首次被INCI列为三聚体，也是首个被收录的重组三螺旋胶原蛋白，并将“三螺旋”直接接受为有结构的胶原蛋白商品名，这标志着粒影生物三螺旋重组胶原蛋白正式走向国际市场。
Shenzhen LiYing Biotechnology Co., Ltd.'s recombinant triple-helix collagen has been officially included in the International Nomenclature of Cosmetic Ingredients (INCI) directory (INCI No. 40302). This marks the first time collagen has been listed by INCI as a trimer, with the "Tri-helix" directly recognized as structured collagen. It signifies that LIYING BIO's recombinant triple-helix collagen is now officially entering the international market.
图一：INCI分配信
Figure 1. INCI Assignment Letter
INCI名称是国际公认用于识别化妆品成分的系统名称，由国际命名委员会(International Nomenclature Committee，简称为INC)审核和分配，并由美国个人护理产品协会(Personal Care Products Council，简称为PCPC)发布在《国际化妆品成分字典和手册》中。这些名称在全球范围内被认可，用于识别化妆品成分，旨在确保化妆品成分的准确性和一致性。
The INCI name is an internationally recognized system for identifying cosmetic ingredients. They are reviewed and assigned by the International Nomenclature Committee (INC), and published by the Personal Care Products Council (PCPC) in the International Cosmetic Ingredient Dictionary and Handbook. These names are globally accepted for identifying cosmetic ingredients, ensuring accuracy and consistency in cosmetic formulations.
粒影生物的三螺旋胶原蛋白结构稳定、功效强，生物相容性好，具有显著的抗衰、修复、抗皱和美白功效，不仅能应用在护肤和日化领域，还能够应用于临床医学，如医美填充、创面修复及骨科等领域。此外，其耐高温特性使其能够适应多种生产与应用环境。
LIYING BIO's Tri-helix collagen features a stable structure, high efficacy, and excellent biocompatibility, delivering remarkable anti-ageing, reparative, anti-wrinkle, and brightening benefits. Beyond skincare and personal care applications, it is also suitable for clinical medical uses, such as aesthetic fillers, wound repair, and orthopaedic treatments. Additionally, its heat-resistant properties enable versatile adaptation to diverse production and application environments.
图二：结构与功能验证
Figure 2. Structural and Functional Verification
图三：毒理检测报告
Figure 3. Toxicology Test Report
粒影生物通过生物合成的方法，结合人工智能计算、设计、改造获得高活性蛋白质，构建高适配工程菌株，实现了具有三螺旋结构的重组人源化胶原蛋白的成功表达和高效生产，并形成以ZL 202410624084.X等十余项核心专利、二十多项外围专利的技术包，同时布局海外专利，筑起专利墙。凭借这些创新成果，粒影生物获得了多项荣誉与资质。
LIYING BIO employs synthetic-biology approaches, integrating AI-powered computation, design, and modification to develop highly active proteins. The company has successfully constructed high-efficiency engineered bacterial strains capable of expressing and producing recombinant humanized collagen with a stable Tri-helix structure. Backed by a robust IP portfolio - including core patents such as ZL 202410624084.X (with over 10 core patents and 20+ peripheral patents) and strategic international patent filings - LIYING BIO has established a comprehensive patent protection system. These technological breakthroughs have earned the company numerous prestigious awards and certifications in recognition of its innovations.
图四：自主发明专利
Figure 4: Independent Invention Patents
图五：获奖情况
Figure 5: Awards
图六：奖励证书
Figure 6: Award Certificate
目前，粒影生物的三螺旋胶原蛋白已经成功应用于市场，并在多个领域展现出巨大的应用潜力，自主研发的护肤品牌Tri-helix于2024年底正式上线，并受到消费者一致好评。
Currently, LIYING BIO 's Tri-helix collagen has been successfully commercialized and demonstrates significant potential across multiple applications. The company's proprietary skincare brand, Tri-helix, officially launched in late 2024 and has received unanimous acclaim from consumers.
图七：顾客反馈
Figure 7：customer feedback
